Solriamfetol beneficial for adults with attention-deficit/hyperactivity disorder, shows clinical trial

By the end of the study, a greater proportion of individuals taking solriamfetol had improved measures on all of these scales, when compared with patients taking placebo.

Solriamfetol had no significant effect on sleep quality as evaluate by the Pittsburgh Sleep Quality Index, or on average heart rate or blood pressure. Adverse experiences that occurred at a higher numerical rate than placebo fell under the categories of decreased appetite, headache, gastrointestinal symptoms, insomnia, increased energy, cardiovascular and neurologic effects.

“Our results suggest that solriamfetol may be a safe and effective treatment for ADHD in adults. Larger studies replicating these findings could confirm the strong evidence of benefit and the tolerability of this agent as a treatment,” says lead author Craig B.H. Surman, MD, the Director of the Clinical and Research Program in Adult ADHD at MGH and Associate Professor of Psychiatry at Harvard Medical School. “Although there are currently safe and effective treatments for ADHD, they are not effective for all individuals with ADHD or tolerated well by all patients. Our findings offer hope of a new method of supporting the daily challenges that individuals with ADHD face.”

Reference:

Craig B. H. Surman, Daniel M. Walsh, Nora Horick, Maura DiSalvo, Chloe Hutt Vater,and Daniel Kaufman, Solriamfetol for Attention-Deficit/Hyperactivity Disorder in Adults: A Double-Blind Placebo-Controlled Pilot Study, DOI:10.4088/JCP.23m14934.